Pubblicato su advances in hematology and oncology research
Breast cancer is the first and most common cancer in women and represents the leading cause of female cancer death. To treat cancer, the treatment that is giving more results is the conventional polychemotherapy with numerous other substances that have specific action, called target therapy. During the treatment of breast cancer, chemotherapy drugs lead to the frequent detection of side effects, first of all, the Oral Mucositis. Oral mucositis (OM) is a common in cancer therapy, found in a percentage of 15-40%, and cause severe sequelae and strong impact on a patient’s quality of life (QoL), health care costs, and ultimately outcome by influencing the treatment dose. There are some and limited therapeutic options to help reduce the severity of OM. Our study evaluated the action of a mix of natural supplements (swallowable solution,
Orasol plus®, for reduction of mucositis during chemotherapy, with Lapacho (Tabebuia Avellanedae Lorentz ex Griseb.), Camellia Sinensis L. Kuntze, Calendula Officinalis L, Malva Sylvestris L, Sisymbrium Officinale (L) Scop, Plantago Major L e Propoli) in 15 breast cancer patients under treatment with chemotherapy and target therapy. No patients had stopped the treatment because of mucositis. From 11 patients that have mucositis during treatment, 5 had complete remission at the and of the first cycle in the 4 patients who took Orasol Plus®, as a preventive measure, none developed mucositis during antiblastic treatments. The data of our study depose for the effectiveness of Orasol Plus® in the treatment of oral mucositis, in patients undergoing chemotherapy for breast cancer. They need a larger study to insert Orasol Plus® in a standardized pathway in the treatment of oral mucositis during chemotherapy.